Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eli Lilly and Company